Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 plus Nab-paclitaxel and Gemcitabine in Advanced Pancreatic Cancer
NCT06750861Phase 2Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Feb 2025
- Primary completion
- Jun 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of QL1706 in pancreatic ductal adenocarcinoma (PDAC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Objective Response Rate at 1 year and Incidence of Treatment-Emergent Adverse Events at 1 year. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06750861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06750861.